Russia extends production of COVID-19 drug remdesivir without patent for a year

James B. Beal
ab35afd02359d86e429a8b955c7cef70

An ampule of Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS

An ampule of Remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (COVID-19) continues. Ulrich Perrey/Pool via REUTERS

MOSCOW, Dec 30 (Reuters) – The Russian government extended on Thursday its approval for drugmaker Pharmasyntez to produce a generic version of U.S. anti-COVID-19 drug remdesivir without a patent for one year, citing the need to protect its citizens.

Pharmasyntez asked the Kremlin to allow it to produce a generic version of U.S. COVID-19 drug remdesivir in November 2020 without consent from U.S. company Gilead Sciences (GILD.O) that holds the patent.

Russia's Supreme Court in May rejected a lawsuit from Gilead Sciences that challenged the decision to let Pharmasyntez develop and market remdesivir. read more

The governmental decree published on Thursday said Pharmasyntez has to pay compensation to the drug's patent-holder, without specifying the amount.

Pharmasyntez produces remdesivir under the name Remdeform. A shipment of the drug was sent by Russia to India as part of a delivery of humanitarian aid.

Source

Total
2
Shares
Leave a Reply

Connect with



Your email address will not be published.

Previous Post
aa6310c2b9e8aa1ccbc3d2986112315a

Denmark stocks higher at close of trade; OMX Copenhagen 20 up 0.71%

Next Post
c1f3bc3205ebbb74136622253aa84c0e

Scientists to test high dexamethasone doses in severely ill COVID-19 patients

Related Posts